Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin

Y Andersson*,1,5, O Engebraaten1,2,3,5, S Juell1, S Aamdal3,4, P Brunsvig4, Ø Fodstad1,3,6 and S Dueland2,6

1Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0424 Oslo, Norway; 2Department of Oncology, Oslo University Hospital, 0424 Oslo, Norway; 3Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0424 Oslo, Norway and 4Department of Clinical Cancer Research, Oslo University Hospital Radiumhospitalet, 0424 Oslo, Norway

Background: A phase I trial was performed to determine the maximum tolerated dose (MTD), safety, pharmacokinetics and immunogenicity of the anti-EpCAM immunotoxin (IT) MOC31PE in cancer patients. An important part of the study was to investigate whether the addition of Sandimmune (cyclosporin, CsA) suppressed the development of anti-IT antibodies.

Methods: Patients with EpCAM-positive metastatic disease were eligible for treatment with intravenous MOC31PE using a modified Fibonacci dose escalation sequence. Maximum tolerated dose was first established without, then with intravenously administered CsA.

Results: Sixty-three patients were treated with MOC31PE in doses ranging from 0.5 to 8 mg/kg/C0.1. Maximum tolerated dose was 8 mg/kg/C0 for MOC31PE alone, and 6.5 mg/kg/C0 when combined with CsA. The dose-limiting adverse event was reversible liver toxicity. No radiological complete or partial responses were observed, whereas stable disease was seen in 36% of the patients receiving MOC31PE only. The pharmacokinetic profile of MOC31PE was characterised by linear kinetics and with a half-life of ∼3h. The addition of CsA delayed the generation of anti-IT antibodies.

Conclusions: Intravenous infusion of MOC31PE can safely be administered to cancer patients. Immune suppression with CsA delays the development of anti-MOC31PE antibodies. The antitumour effect of MOC31PE warrants further evaluation in EpCAM-positive metastatic disease.

Tumour therapies targeting EpCAM have been extensively investigated, particularly because the antigen is overexpressed in epithelial tumours, cancer stem cells and circulating tumour cells (van der Gun et al, 2010; Schnell et al, 2013). The therapeutic strategies include both naked antibodies and antibodies armed with a cell killing moiety, for example, cytotoxic drugs or toxins. Immunotoxins (ITs) are bifunctional proteins composed of an antibody and a toxin moiety (Alewine et al, 2015). In cancer, the antibody can deliver the toxin to cell-surface antigens expressed on the malignant cells, theoretically leaving normal cells unaffected. When internalised into the cells, the toxin moiety triggers cell death by catalytically inactivating vital processes, such as protein synthesis, and by directly inducing apoptosis (Andersson et al, 2004; Antignani and Fitzgerald, 2013).

The first-generation ITs consisted of an intact murine monoclonal antibody covalently linked to the whole toxin, later followed by the second generation in which the cell binding domain of the toxin was deleted (Antignani and Fitzgerald, 2013). The third
generation of ITs consists of recombinant ITs (Antignani and Fitzgerald, 2013), supposed to be better tailored to their purpose. Their small size would assure better tumour penetration, and the immunogenic fragments and non-specific targeting moieties were modified. Unfortunately, none of the clinical trials with ITs in solid tumours has so far been successful. The only first-generation IT containing intact Pseudomonas exotoxin A (PE) (Pai et al., 2019), in phase I trials in humans with prostate cancer, but no effect on tumour recurrence was observed. The target antigen was found to be expressed also in CNS, and this resulted in dose limiting toxicity (DLT) and even had lethal consequences.

The importance of antibody selection and antigen specificity has been experienced in several clinical trials (Pai-Scherf et al., 1999), and unanticipated clinical toxicity of many ITs, such as vascular leak syndrome (VLS) and neurotoxicity, seems to be caused mainly by non-specific binding of the targeting antibody (Andersson et al., 2009).

The toxicity of PE has been the main limitation with the first-generation ITs. Many ITs have, in spite of all technological advances in the development of second and third generation of ITs, they have not fulfilled the expectations, with hepatotoxicity as the most common side effect. In an attempt to overcome this, we tested the combination of the IT and the immuno- targeting antibody, and intratumorally in mice with liver cancer, and intratumorally in head and neck cancer. Some evidence of antitumour effect and limited drug-related toxicity was reported (MacDonald et al., 2009; Kowalski et al., 2009), but to our knowledge PE38 has not been administered intravenously (i.v.). In retrospect, it is clear that in spite of all technological advances in the development of second and third generation of ITs, they have not fulfilled the expectations, with hepatotoxicity as the most common side effect.

We have previously shown that our MOC31PE IT, consisting of a murine monoclonal antibody covalently linked to intact PE, had potent antitumour effects in vitro and in animal models (Engbraaten et al., 2000; Andersson et al., 2004, 2009; Hjortland et al., 2004; Risberg et al., 2010, 2011; Flatmark et al., 2013; Wiiger et al., 2014).

However, one main limitation with the first-generation ITs is the early development of neutralising antibodies, limiting the efficacy of repeated therapeutic courses. In attempts to overcome this, we tested the combination of the IT and the immunosuppressive drug Sandimmune (cyclosporin, CsA), and found in immunocompetent animals that CsA abrogates the IT-induced immune response. Furthermore, we observed that the combination surprisingly exerted synergistic therapeutic effects in vitro and in a nude rat model for cervical cancer (Andersson et al., 2009), results that encouraged us to initiate a clinical trial with MOC31PE as monotherapy, followed by a combination study with CsA.

**MOC31PE.** The MOC31 monoclonal mouse antibody (IgG1) recognising the CD326 antigen (EpCAM) was produced and purified to clinical grade by MCA Development, Groningen, The Netherlands. PE was isolated from the fermentation broth of Pseudomonas aeruginosa PA103, manufactured at University of Ohio, Columbus, OH, USA. MOC31PE conjugate was produced to clinical grade at Fred Hutchinson Cancer Research Center, Biologics Production Facility, Seattle, WA, USA by conjugating MOC31 with PE by a thioether bond formed with the reagent sulfo-SMCC (sulfo-succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate) (Pierce, Rockford, IL, USA) (Godal et al., 1992). MOC31PE was prepared for clinical use at a concentration of 0.5 mg ml⁻¹ in 20 mM phosphate-buffered saline (PBS), pH 7.4 and 0.1% human serum albumin (HSA, clinical grade).

**Ethical.** The rodent studies were approved by the National Animal Research Authority and carried out according to the European Convention for the Protection of Vertebrates used for Scientific Purposes. The clinical phase I study was approved by the Norwegian Medicines Agency, by the Norwegian Regional Ethical Committee and by the institutional review board. The registration number is NCT01061645 with the study title ‘Study of MOC31-PE in antigen positive carcinomas’.

**Toxicology studies in mice and monkey.** The LD50 level of MOC31PE was assessed in BALB/c mice. MOC31PE (50, 100, 150, 200, 250 and 500 μg kg⁻¹) were administered by a single i.v. injection, in a volume of 0.2 ml in PBS/0.1% HSA via the lateral tail vein, with a 14-day observation period. Control animals received vehicle only.

The toxicological evaluation of MOC31PE in cynomolgous monkeys (Macaca fascicularis) was performed at Covance Laboratories Inc, Vienna, VA, USA. MOC31PE was administered as a single dose i.v. in two animals per doses (30 and 150 μg kg⁻¹) and two animals received repeated dose of 30 μg kg⁻¹ at days 1 and 7. Control animals received the drug vehicle. Parameters monitored included clinical symptoms, mortality, changes in body weight and food consumption, haematology, coagulation, and serum biochemical tests were performed on days 2, 4, 8, 15, and 21 after the first cycle. Each group was observed for at least 2 weeks post injection.

**Patients.** Eligible patients with metastatic disease were 18 years of age or older with histologically confirmed epithelial carcinoma positive for EpCAM (CD326) by immunocytochemical/immunohistochemical staining. Formalin-fixed paraffin-embedded tumour tissue was stained with the epithelial-specific antigen (ESA) mouse monoclonal antibody (Clone VU-1D9; Novo Castra Laboratories Ltd, Newcastle, UK). For antigen retrieval low pH and microwave treatment were used, and the antibody staining performed with a 1: 400 dilution of the primary antibody, and visualised using the Dako EnVision system (Dako, Oslo, Norway). The patients were eligible for inclusion into the study if 10% or more of the tumour cells were positive for EpCAM/ESA. The patients had to have ECOG performance status 0–2, neutrophils ≥1.5 × 10⁹ per litre, platelets ≥100 × 10⁹ per litre, creatinine ≤120 μmol l⁻¹, total bilirubin, AST, ALT, ALP, gamma GT (GGT) and coagulation parameters (PT, PTT) all within normal range at the start of the trial.

Major exclusion criteria were clinically symptomatic CNS involvement, the use of coumarin anticoagulants, phenytoin, phenobarbital or systemic steroids, history of hepatitis B or C infection or a HIV diagnosis. Before inclusion and study-related investigations, the patients signed an approved written informed consent.

**Study design.** The phase I dose escalation trial was performed in two parts, the first with modified Fibonacci dose escalation of MOC31PE alone until the maximally tolerated dose (MTD) was reached, and the second part was performed with dose escalation of MOC31PE and concomitant administration of Sandimmune (CsA;
Novartis, Oslo, Norway). The starting dose was determined based on the toxicity in mice and non-human primates, with the toxicity in mice species determining the initial dose.

MOC31PE was diluted with 0.9% saline to a total volume of 250 ml, and infused i.v. over 20 min. This combination was repeated every second week up to four times in total. The starting dose was 0.5 μg kg\(^{-1}\) and dose escalation was performed at the following schedule: 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.5 and 8.0 μg kg\(^{-1}\), with at least three patients at each dose level. After an amendment, repeated administration of MOC31PE was allowed up to a total of eight in patients with partial response or stable disease. One patients received eight infusions (0.5 μg kg\(^{-1}\)) and one six (1.5 μg kg\(^{-1}\)) infusions.

In the second part of the study, MOC31PE was combined with CsA, administered i.v. over 8 h at a fixed dose of 3 mg kg\(^{-1}\) at days 0–4. MOC31PE was administered at day 1 as described above. The dose escalation of MOC31PE was performed at the following levels: 2.0, 3.0, 4.0, 5.0 and 6.5 μg kg\(^{-1}\) with at least three patients treated at each dose level. The combination was repeated every second week up to four times in total. In this part of the study, AST, ALT, ALP and GGT values up to 2.5× upper normal limit at time of inclusion were allowed. In another part of the study, CsA was administered orally, three patients per dose, 3 and 6 mg kg\(^{-1}\) twice daily (morning and evening), received Sandimmune Soft Gelatin Capsules (CsA oral) at days 0–4 and MOC31PE (4 μg kg\(^{-1}\)) was administered i.v. at day 1.

**Patient toxicity.** Maximally tolerated dose was defined as the dose at which two of up to six patients experienced DLT. DLT was defined as haematological toxicity ≥ grade 3, gastrointestinal ≥ grade 3, hepatic ≥ grade 4, coagulation ≥ grade 2, neurological ≥ grade 2, renal ≥ grade 2 or any other ≥ grade 3 toxicity, according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 2.0.

**Radiology evaluation.** Computed tomography (CT) was used to determine tumour response (CR, PR, SD, or PD) by RECIST criteria (Therasse et al, 2000). The CT scans were performed within 4 weeks before first infusion and 8 weeks after first infusion.

**Pharmacokinetic analyses of MOC31PE.** Blood sampling was performed pre-treatment (baseline) and at five time points after the infusion (3, 6, 12, 24 and 48 h) of MOC31PE and the serum was stored frozen until analysed in a quantitative sandwich ELISA to detect MOC31PE. A monoclonal antibody rat anti-mouse IgG1 (LO-MG1-13, Abcam, Cambridge, UK) was pre-coated onto a FluoroNunc 96-well plate. Patient serum or standard samples were added into the wells, in addition to the assay buffer (Bjerner et al, 2005). Biotinylated MOC31 antibodies were attached to streptavidin-coated microplates, by incubation for 30 min with continuous shaking in room temperature. The plates were washed six times with washing buffer, as above. Patient serum or standard was diluted 1:4 in assay buffer (Bjerner et al, 2002) with addition of 0.1% Octapharma HSA (Octapharma PGPbH, Vienna, Austria) to each well. After incubation with shaking for 1 h, the plates were again washed six times and 150 µl of europium-labelled tracer antibody conjugated to MOC31PE was added to each well. The plates were thereafter handled as previously described (Warren et al, 2005). The anti-MOC31PE antibody values (AU ml\(^{-1}\)) were plotted against a standard curve.

**Assessment of the neutralising activity of anti-MOC31PE antibodies.** The neutralising effect of human anti-MOC31PE antibodies on MOC31PE-induced inhibition of cell viability was measured using the CellTiter 96 Aqueous One Solution (MTS-assay) (Promega, Madison, WI, USA). MA11 breast cancer cells were seeded in 96-well plates at 10 000 cells/well and grown to about 80% confluences in RPMI (Andersson et al, 2004). The old medium was replaced with new medium containing MOC31PE (10 ng ml\(^{-1}\)) plus either serum from patients treated with MOC31PE or MOC31PE + CsA or serum sampled before treatment (diluted to 0.25%, 0.125%, 0.0625% and 0.03125% in medium) and incubated at 37°C for 24 h. The CellTiter 96 Aqueous One Solution was then added to the wells, and the absorbance was measured 2–4 h later at a wavelength of 490 nm. The viability of MOC31PE-treated cells with MOC31PE – or MOC31PE + CsA – patient serum added were compared with the values for untreated control cells and recorded as the percentage cell viability of control cells. The assays were performed in triplicate, and repeated at least three times.

**Immunomagnetic detection of micrometastatic cancer cells in bone marrow.** Samples of 10–20 ml bone marrow (BM) were aspirated from the posterior iliac crest through aspiration needles, as described (Eide et al, 2009). After BM aspiration, the sample was immediately assayed for the presence of micrometastatic cells. Briefly, the total number of mononuclear cells (MNCs) was counted and the immunomagnetic beads (Dynabeads M450 rat anti-mouse IgG1) coated with MOC31 antibody (IQ Products, Groningen, the Netherlands) were then added to the cell suspension (2 × 10^7 MNCs). A sample was classified as positive when at least 10 rosetted cells (i.e., cells with membrane-bound beads) out of the total of 2 × 10^7 MNC are present. No rosettes were observed with uncoated control beads.

**Statistical analysis.** Statistical calculations were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA) for Windows. Mann–Whitney and Pearson’s Chi square tests were used for statistical analysis. P<0.05 was considered to be statistically significant.

**RESULTS**

**Preclinical toxicity.** In preclinical studies, the LD50 of MOC31PE in mice was found to be 100 μg kg\(^{-1}\) with an estimated LD10 of 60 μg kg\(^{-1}\). According to human equivalent dose (HED), a safe starting dose in humans would be 0.5 μg kg\(^{-1}\) (Freireich et al, 1966). Due to the lack of cross reactivity of MOC31 with murine EpCAM, cynomologous monkeys were used for assessing the toxicity of systemically administered MOC31PE (30 μg kg\(^{-1}\)) as a single dose (two animals) or two doses 1 week apart (two animals) and MOC31PE was well tolerated with no clinical signs, changes in body weight or histopathologic alterations indicating toxicity. The clinical pathology data were indicative of a hepatic insult, with elevation of liver enzymes (AST/ALT) reaching peak values within few days after administration before gradual normalisation. The 30 μg kg\(^{-1}\) dose in monkeys is comparable to a dose of 10 μg kg\(^{-1}\) in humans (Freireich et al, 1966).
One monkey (female) given 150 μg kg⁻¹ MOC31PE (HED = 50 μg kg⁻¹) had a moderate increase in liver enzyme levels (AST (6480) and ALT (5160) (U l⁻¹)) 2 days after treatment, and was found dead the following day. Histopathological examination showed diffuse hepatocellular degeneration/necrosis. The other monkey receiving the same dose had a transient increase in liver enzymes with a peak (AST (6480) and ALT (5160) (U l⁻¹)) 4 days after drug administration before recovering. In this case, focal areas of chronic active inflammation were seen at autopsy at the end of the observation period.

**Patient characteristics.** This study was conducted in three parts. Thirty-four patients were included in the MOC31PE only part (Table 1). In the second part, IT was administered (day 1) in combination with a fixed i.v. dose of CsA (3 mg kg⁻¹) at days 0–4 in 23 patients (Table 1).

In the third part of the study, a fixed i.v. dose of MOC31PE (4 μg kg⁻¹ day 1) was administered with CsA given orally. Three patients per dose of CsA (3 or 6 mg kg⁻¹ twice daily, days 0–4) were included (Table 1).

**Radiological response.** Antitumour activity was assessed by CT scan 8 weeks after the first MOC31PE administration. For the 33 patients who could be evaluated for radiological response to MOC31PE alone, no complete or partial responses were obtained, 12 (36%) had stable disease and 21 (64%) had progressive disease.

---

**Table 1. Baseline characteristics of patient populations**

| MOC31PE     | MOC31PE + CsA i.v. | MOC31PE + CsA per os |
|-------------|--------------------|----------------------|
| Patients, n | 34                 | 23                   | 6                    |
| Age (range) | 57 (40–75)         | 63 (47–78)           | 65 (59–71)           |
| Sex, n (%)  |                    |                      |                      |
| Women       | 14 (41)            | 11 (48)              | 3 (50)               |
| Men         | 20 (59)            | 12 (52)              | 3 (50)               |
| ECOG, n (%) | Grade 0            | 25 (74)              | 14 (61)              | 2 (33) |
| Grade 1     | 9 (26)             | 8 (35)               | 4 (67)               |
| Grade 2     | 0 (0)              | 1 (4)                | 0 (0)                |
| Tumour type, n (%) | CRC | 15 (44) | 18 (74) | 4 (67) |
|             | NSCLC              | 12 (35)              | 3 (13)               | 0 (0) |
|             | Pancreatic         | 3 (9)                | 1 (4.5)              | 2 (33) |
|             | Other              | 4 (12)               | 1 (4.5)              | 0 (0) |

Abbreviations: CRC = colorectal cancer; CsA = cyclosporin; ECOG = eastern cooperative oncology group; i.v. = intravenous; NSCLC = non-small-cell lung cancer.

---

**Table 2. Number of patients with adverse events after first cycle of MOC31PE**

| MOC31PE     | MOC31PE + CsA i.v. | MOC31PE + CsA per os |
|-------------|--------------------|----------------------|
| MOC31PE (μg kg⁻¹) | 0.5 | 1 | 1.5 | 2 | 3 | 4 | 5 | 6.5 | 8 | 2 | 3 | 4 | 5 | 6.5 | 4 |
| Total patients included | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 7 | 3 | 3 | 6 | 5 | 6 | 6 |
| AST/ALT grade 3 (n=patient) | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 3 | 1 | 2 | 1 | 1 | 1 | 3 | 3 |
| AST/ALT grade 4 (n=patient) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 2 | 2 | 1 |
| Pain/fatigue grade 3 (n=patient) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |

Abbreviations: AES = adverse events; AST = aspartate aminotransferase; ALT = alanine aminotransferase; CsA = cyclosporin; i.v. = intravenous. The first row shows the dosages of MOC31PE administered in the different subseries. Second row shows the total number of patients per dose level included at each MOC31PE dose. Third row shows the number of patients with clinical grade 3 toxicity and fourth row shows the number of patients with clinical grade 4 toxicity determined by elevated AST and/or ALT levels per MOC31PE dose level. The last row shows the other grade 3 AES observed. No other AES than hepatotoxicity in MOC31PE + CsA per os were observed. The criteria for toxicity are according to the National Cancer Institute Common Toxicity Criteria version 2.0. Grade 3 is determined as 5–20 times increase and grade 4 is determined as a more than 20 times increase of AST and/or ALT in blood compared with upper normal limit.
patient (MOC31PE alone, 4 μg kg⁻¹) suffered from pain and one patient (MOC31PE + CsA; 6.5 μg kg⁻¹) from fatigue and pain. These AEs were most likely related to disease progression, as the two patients had bone metastases and received palliative radiation therapy.

Other minor toxicities (CTC grade 2) were registered in seven patients with MOC31PE (21%) and six patients with MOC31PE + CsA (22%) (data not shown). Most of the patients with grade 2 nausea, fatigue or anorexia had these adverse events due to CsA treatment, as they appeared before MOC31PE administration. No adverse events were reported with oral CsA medication. With regard to s-albumin, creatinine, bilirubin, CRP and alkaline phosphate levels only grade 1 toxicities were noted, except that one patient in MOC31PE alone had elevated bilirubin, from 10 to 39 μmol l⁻¹ (grade 2) on day 7 in cycle 2.

MOC31PE pharmacokinetics. The serum level of MOC31PE 3 h post treatment increased with increasing doses (Figure 1 and Table 3). At 0.5–2 μg kg⁻¹ MOC31PE alone, the measured serum level was 8.1 (s.d. = 3.6) ng ml⁻¹. For most patients at dose levels of 3–6.5 μg kg⁻¹, the serum contained <10 ng ml⁻¹ of MOC31PE, even as late as 12 h post treatment (not shown). Cyclosporin had no influence on MOC31PE serum level (Table 3). The pharmacokinetic curves for MOC31PE at doses from 3 to 6.5 μg kg⁻¹ showed similar slopes (Figure 2). The Mann–Whitney Rank sum test on each dose level does not detect any significant difference between the MOC31PE and the MOC31PE + CsA groups. However, the results should be interpreted with caution due to the small number of patients at each dose level.

No serum sample was taken immediately after MOC31PE administration, but estimation of a distribution volume of 3.33 l may be used for predicting the initial dose (Gupta et al, 2012). The estimated initial concentration would be 137 ng ml⁻¹ for a 70 kg patient given 6.5 μg kg⁻¹ of MOC31PE. The measured MOC31PE concentration at 3 h post treatment was ~60 ng ml⁻¹, suggesting that the half-life of MOC31PE is around 3 h (Figure 2).

CsA delayed anti-MOC31PE antibodies development. The presence of neutralising anti-MOC31PE antibodies in serum was examined in a MOC31PE-induced cytotoxicity assay (MTS assay) (Figure 3 and Supplementary Figure 1a and b). In the presence of anti-MOC31PE antibodies in the serum, the cytotoxic effect of MOC31PE would be partly or fully neutralised.

In MOC31PE alone study, 2 weeks after the first cycle with MOC31PE treatment, 9 of the 29 patients (31%) had developed neutralising anti-MOC31PE antibodies, compared with only 19% in MOC31PE + CsA study. The CsA delayed anti-MOC31PE antibodies development.

Table 3. Plasma concentration of MOC31PE 3 h after the first administration cycle of MOC31PE as measured by ELISA

| Dose level (μg kg⁻¹) | No. of patients with serum samples taken in MOC31PE alone | MOC31PE in serum 3 h post treatment (ng ml⁻¹) | No. of patients with serum samples taken in MOC31PE + CsA i.v. | MOC31PE in serum 3 h post treatment (ng ml⁻¹) |
|----------------------|----------------------------------------------------------|---------------------------------------------|----------------------------------------------------------|---------------------------------------------|
| 0.5                  | 2                                                        | 3, 5                                        | 0                                                        | 0                                           |
| 1.0                  | 3                                                        | 5, 9, 11                                    | 0                                                        | 0                                           |
| 1.5                  | 3                                                        | 4, 13, 13                                   | 0                                                        | 0                                           |
| 2                    | 3                                                        | 6, 9, 11                                    | 3                                                        | 16, 18, 35                                  |
| 3                    | 2                                                        | 7, 41                                       | 2                                                        | 13, 28                                      |
| 4                    | 3                                                        | 9, 30, 47                                   | 2                                                        | 19, 55                                      |
| 5                    | 3                                                        | 44, 49, 51                                  | 2                                                        | 9, 49                                       |
| 6.5                  | 2                                                        | 56, 63                                      | 3                                                        | 52, 58, 73                                  |

Abbreviations: CsA = cyclosporin; i.v. = intravenous. No serum samples at MOC31PE 8 μg kg⁻¹ were collected.
(4 of 21 patients) in MOC31PE + CsA, most likely reflecting the immunosuppressive function of CsA (Figure 3). However, the statistical difference was not significant. This effect was even more pronounced 2 weeks after the second cycle, where 77% (24 of 31) of the patients treated with MOC31PE alone had neutralising antibodies, compared with only 29% (6 of 21) of the patients receiving MOC31PE and CsA, \( P < 0.05 \). Moreover, at 6 weeks after treatment start (third cycle of MOC31PE), almost all of the patients in MOC31PE alone had developed antibodies (27 of 28) whereas the immunosuppressive effect of CsA was still clear, as only 50% (10 of 20) of these patients had antibodies, \( P < 0.05 \). With an ELISA, we measured the levels of anti-MOC31PE antibodies (data not shown). The ELISA data showed an overall accordance to the MTS data. Fetal calf serum and serum from healthy volunteers had no effect on MOC31PE-induced cytotoxicity in M11 cells (data not shown).

Presence of micrometastatic cancer cells in BM. Bone marrow samples, four out of six patients treated with \( 4 \mu g \cdot kg^{-1} \) of MOC31PE and three out of five patients treated with \( 5 \mu g \cdot kg^{-1} \), were taken in the MOC31PE + CsA study at baseline and 2 weeks post treatment (Figure 4). No obvious cytotoxic effect of MOC31PE on the presence of micrometastatic cells in BM was detected in patients treated with \( 4 \mu g \cdot kg^{-1} \) of MOC31PE. Interestingly, at \( 5 \mu g \cdot kg^{-1} \) of MOC31PE the number of EpCAM-detected tumour cells decreased from baseline to 2 weeks post treatment by 36%, 74% and 91%. These patients had no anti-MOC31PE antibodies even after four cycles of MOC31PE, indicating that MOC31PE most likely was cytotoxic in all cycles. Mainly due to the lack of consent for BM sampling, none of the patients treated with higher doses of MOC31PE were examined for micrometastatic cancer cells.

**DISCUSSION**

In this phase I trial, we have shown that the EpCAM-targeting MOC31PE could safely be administered i.v., and it was well tolerated, both given alone (34 patients) and in combination with CsA (29 patients). Cyclosporin effectively delayed the development of neutralising anti-MOC31PE antibodies, thereby allowing for repeated IT administration. With the lack of an overall benefit reported in clinical trials with modified and recombinant ITs, we hypothesised that the native functional domains of the toxin should be intact for optimal stability and cytotoxicity, and therefore we developed and characterised our unmodified IT. Based on extensive and promising preclinical studies in vitro and in experimental human tumour models in vivo, we initiated and performed a successful clinical phase I study with MOC31PE in patients with advanced carcinomas. To avoid accumulated toxicity, an administration schedule with IT infusion every other week was chosen. Interestingly, only 3 out of 7 patients treated at the MTD had AST and/or ALT > 5 × the upper limit of normal, and the toxicity was limited to a transient increase in serum transaminases. Apart from hepatotoxicity, only two patients were recorded with grade 3 AEs, fatigue and pain, and these AEs were most likely related to disease progression and not MOC31PE according to the clinical disease present.

The adverse event profile of antibody-based drugs varies depending on composition, drug target and the individual patient. MOC31PE recognises the EpCAM antigen that is frequently and highly expressed on epithelial carcinomas. The effect of liver function tests could be attributed to the expression of EpCAM on the small bile ducts (Went et al, 2006). However, in normal tissue, EpCAM is arranged in a complex with several interacting proteins and is localised to basolateral membranes. The accessibility for EpCAM-binding antibodies is lower in normal cells than in cancer cells where EpCAM might be better accessible for targeting antibodies (Schnell et al, 2013). Furthermore, MOC31PE is highly selective for malignant cells, with low toxicity to normal tissues in part due to ‘shielding’ of EpCAM by the organisation of the surface of the normal epithelial tissues. EpCAM is an interesting target also as EpCAM-positive cancer cells are proposed to be more aggressive than EpCAM-negative cancer cells (van der Gun et al, 2010; Schnell et al, 2013), whereas some groups have reported its expression to be downregulated in, for example, circulating tumour cells (Rao et al, 2005; Steinert et al, 2014). However, our data on breast cancer lymph node cells show EpCAM positive even in tumour cells having undergone epithelial–mesenchymal transition (Tveito et al, 2011). In addition to the MOC31PE alone study, we expanded the phase I trial to include CsA (3 mg kg\(^{-1}\) i.v.) in...
combination with MOC31PE. We recently published that CsA efficiently reduced the neutralising anti-IT antibody response when IT was repeatedly administered in immunocompetent animals. Cyclosporin has been shown to enable repeated administration of monoclonal antibody therapy in patients by reducing the human anti-mouse antibody (HAMA) response (Ledermann et al, 1988; Weiden et al, 1994).

No objective tumour response (complete or partial remission) was seen by CT scan 8 weeks after the first MOC31PE infusion. Based on the present knowledge on response to repeated immunotherapy treatment, it is possible that the clinical benefit of the treatment may be underestimated based on only the CT at week 8. In the MOC31PE alone study, 12 patients (36%) had stable disease compared with only 3 patients (15%) in the MOC31PE + CsA part. However, the incidence of stable disease shows no dose dependency in either the MOC31PE or MOC31PE + CsA part. Because of the low number of patients at each dose, no clear conclusion can be drawn. Our results imply that the combination of IT + CsA in the clinic may have a promising potential allowing repeated administration of MOC31PE, which is considered to be a necessity for significant anticancer effects in non-haematological cancers. Of note, oral CsA reduced antibody formation against MOC31PE antitumour activity.

Another EpCAM-targeting molecule is catumaxomab, a trivalent antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. Of interest is the fact that catumaxomab is currently undergoing clinical trials in combination with CsA to delay the development of neutralising anti-IT antibodies. The encouraging results of this study warrant a phase II study to further examine the potential of IT being administrated with CsA.

In conclusion, we have demonstrated that the EpCAM targeted immunotoxin and cyclosporin in vitro and in vivo. Br J Cancer 101: 1307–1315.

Antignani A, Fitzgerald D (2013) Immunotoxins: the role of the toxin. Toxins 5: 1486–1502.

Bjerner J, Nutstad K, Nustad K, Olsen LF, Olsen KH, Borner OP (2002) Immunomodulatory cytokine interference: effects and cytokine assay interference: incidence and prevention. Clin Chem 48: 613–621.

Eide N, Faye RS, Hoifodt HK, Overgaard R, Jepsen P, Kvalheim G, Fodstad O (2009) Immunomagnetic detection of micrometastatic cells in bone marrow in uveal melanoma patients. Acta Ophthalmol (Copenhagen) 87: 830–836.

Engbrecht O, Sivam G, Juel S, Fodstad O (2000) Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats. Int J Cancer 88: 970–976.

Eskander RN, Baruah J, Nayak R, Bruseke T, Ji T, Wardhe R, Tewari KS (2013) Outside slide review in gynecologic oncology: impact on patient care and treatment. Int J Gynecol Pathol 32: 293–298.

Flatmark K, Borgen E, Nesland JM, Rasmussen H, Johannessen HO, Bukholm I, Rosales R, Harklau L, Jacobsen HJ, Sandstad B, Boye K, Fodstad O (2011) Disseminated tumour cells as a prognostic biomarker in colorectal cancer. Br J Cancer 104: 1434–1439.

Flatmark K, Guldvik IH, Svensson H, Flenet KG, Floresen VA, Reed W, Giercksky KE, Fodstad O, Andersson Y (2013) Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies. Int J Cancer 133: 1497–1506.

Freireich EJ, Gohan EA, Ball DP, Schmidt LH, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50: 219–244.

Godal A, Kumle B, Pihl A, Juel S, Fodstad O (1992) Immunotoxins directed against the high-molecular-weight melanoma-associated antigen. Identification of potent antibody-toxin combinations. Int J Cancer 52: 631–635.

Gupta M, Lorusso PM, Wang B, Yi JH, Burris 3rd HA, Beeram M, Modi S, Chu YW, Agresta S, Klenecke B, Joshi A, Girish S (2012) Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol 52: 691–703.

Hjortland GO, Garman-Vik SS, Juel S, Olsen OE, Hirschberg H, Fodstad O, Engbrechten O (2004) Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. J Neurosurg 100: 320–327.

Kowalski M, Entwistle J, Cizeau J, Niñoros D, Loewen S, Chapman W, MacDonald GC (2010) A phase 1 study of an intravasally administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients. Drug Des Dev Ther 4: 313–320.

Ledermann JA, Begent RH, Bagshawe KD, Riggs SJ, Searle F, Glaser MG, Green AJ, Dale RG (1988) Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A. Br J Cancer 58: 654–657.

Leong SP, Tseng WW (2014) Micrometastatic cancer cells in lymph nodes, bone marrow, and blood: Clinical significance and biologic implications. CA Cancer J Clin 64: 195–206.

MacDonald GC, Rasamoelisoaso M, Entwistle J, Cizeau J, Bosc D, Cutlherb W, Kowalski M, Spearman M, Glover N (2009) A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Des, Dev Ther 2: 105–114.

McCann S, Akilov OE, Geskin L (2012) Adverse effects of denileukin difitox and their management in patients with cutaneous T-cell lymphoma. Clin J Oncol Nurs 16: E164–E172.
Phase I clinical trial with MOC31PE immunotoxin

BRITISH JOURNAL OF CANCER

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)